



In the Claims

Please amend claim 1 as follows:

21
1. A method of treating a patient having a multidrug-resistant neoplasm having a pathway for resistance including the multidrug-resistance protein MRP, said method comprising the step of inhibiting membrane transport mediated by the multidrug-resistance protein MRP by administering to said patient an effective amount of a compound of Formula I



wherein R₁ is



Y is hydrogen or halo;


R₂ is hydrogen, -OH, or -OCH₃;

R₃ is C₁-C₆ alkyl;


R₄ is hydrogen, -OH, or -OCH₃;

n is 3, 4, or 5;

A is



or



R₅ is hydrogen, C₁-C₆ alkyl, C₂-C₅ alkenyl, C₂-C₅ alkynyl, benzyl, or phenyl;

R₆ is hydrogen or halo;

R₇ is -COOH or 5-tetrazolyl;

T is a bond, -CH₂-, -O-, -C(=O)-, or -S(O)_q-; and

q is 0, 1, or 2;

provided when one of R₂ and R₄ is -OH or -OCH₃, the other of R₂ and R₄ must be hydrogen, or a pharmaceutically acceptable base addition salt or solvate thereof.

REMARKS

Claim 1 has been amended to add the phrase “having a pathway for resistance including the multidrug-resistance protein MRP.” Support for this claim amendment is found in the specification at page 11, lines 15-17 where it is stated that the compounds of the invention may be used on neoplasms having “a pathway for resistance which includes the protein P190 (MRP).” Claim 1 has also been amended to change the phrase “multidrug resistance” to “multidrug-resistance” to correct a typographical error, and the phrase “to said patient” has been added to claim 1.